Immunology / Virology & Vaccines

Patient receiving vaccine
#Covid-19 #EU #Europe #Immunology / Virology & Vaccines #Vaccines

EU’s position as vaccines leader “at risk”, report reveals

The EU has historically been a leader in vaccine research, development and manufacturing, but is now seeing a decline in vaccine research, according to data published by Vaccines Europe (VE). The EU has hosted approximately 20% of global vaccine clinical trials over the past two decades, as well as research… Read More

#News #Trends & Analysis

Vaccine vial and syringe
#Clinical trial #Immunology / Virology & Vaccines #Nipah Virus #University of Oxford

UK scientists prepare for Nipah virus clinical trial

The University of Oxford has revealed that researchers are currently in the advanced stages of preparing for a clinical trial of a Nipah vaccine using the ChAdOx1 vector. The scientists are also working with partners to develop antivirals and monoclonals to treat those infected, according to… Read More

#News

Covid-19 vaccines
#Covid-19 #Covid-19 vaccine #ICON #Immunology / Virology & Vaccines #Phase II trial

Partners to execute next generation Covid-19 vaccines clinical trial

ICON, a healthcare intelligence and clinical research organisation, with the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services, will execute a clinical trial to evaluate the effectiveness of next-generation Covid-19… Read More

#News

Doctor prepares vaccine
#Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines #Phase I trial #Rabies #Replicate Bioscience #srRNA

Phase I trial of next-generation srRNA rabies vaccine

Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies. The trial, which marks the first time a human has been dosed with Replicate’s srRNA technology, will serve as a benchmark for utility in this… Read More

#News

Doctor administering a vaccine to patient
#Alzheimer's #Immune system #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience

Routine vaccines as effective as antibodies against Alzheimer’s

A new study at UTHealth Houston in the US has found that several routine vaccinations are linked to a significant reduced risk of Alzheimer’s disease (AD). Prior vaccination against tetanus and diphtheria, with or without pertussis (Tdap/Td); herpes zoster (HZ), better known as shingles; and pneumococcus… Read More

#News #Trending News

#FDA #Immunology / Virology & Vaccines #Pfizer #Pregnancy #Respiratory syncytial virus

FDA approves RSV vaccine to protect babies from birth

The US Food and Drug Administration (FDA) has approved the first vaccine for pregnant individuals to prevent respiratory syncytial virus (RSV) in infants. Pfizer’s Abrysvo (Respiratory Syncytial Virus Vaccine) was approved for use at 32-36 weeks gestational age of pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD… Read More

#News #Regulatory

#Antibody #Antivirals #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights episode out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Diana Spencer has chosen news stories this week which all discuss pre-clinical research studies… Read More

#News

#Antibody #Antivirals #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Oncology

This week in drug discovery (14-18 August)  

News round-up for 14-18 August by DDW Digital Content Editor Diana Spencer. My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted… Read More

#News

Preparing Covid-19 vaccine for injection
#BioNTech #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Moderna #Novavax #Pfizer #Vaccines

New Covid-19 vaccines ready to slow spread of EG.5

It is believed that new Covid-19 vaccines developed by Pfizer/BioNTech, Moderna and Novavax will be effective against the fast-spreading EG.5 strain. EG.5 or ‘Eris’ has been found in more than 50 countries. It is the most common and fastest growing Covid-19 subvariant in the US, estimated… Read More

#News #Trending News

Illustration of a virus
#Antivirals #Drug resistance #Immunology / Virology & Vaccines #New York University

Next-generation antivirals could target virus membranes

Researchers have shown that a group of novel molecules inspired by our own immune system inactivates viruses like Zika and chikungunya, and could help overcome antiviral resistance. “We found an Achilles heel of many viruses: their bubble-like membranes. Exploiting this vulnerability and disrupting the membrane is… Read More

#Editor's Choice #News

Conference speaker
#AusBiotech #Australia #Biotechnology #Events #Immunology / Virology & Vaccines

Ian Frazer revealed as keynote speaker for AusBiotech 2023

Emeritus Professor Ian Frazer, University of Queensland and Director of Microba, has been announced as the Millis Oration keynote speaker for AusBiotech 2023. The title of his presentation will be ‘Navigating the future: Predictions and potential of Australian biotechnology’. He will share his assessment… Read More

#News

Child with respiratory syncytial virus
#Immunology / Virology & Vaccines #Meissa Vaccines #Paediatrics #Phase I trial #Respiratory syncytial virus

‘Compelling’ data for paediatric live attenuated RSV vaccine

A new respiratory syncytial virus (RSV) vaccine candidate has achieved positive safety and immunogenicity results in a Phase I clinical study of RSV-naïve participants between the ages of six and 36 months. MV-012-968 is being developed by Meissa Vaccines as a needle-free, adjuvant-free vaccine to protect… Read More

#News

Vaccine research
#Covid-19 #Disease X #Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response #UK

UK vaccine centre offers opportunity for pandemic preparedness

A new Vaccine Development and Evaluation Centre (VDEC) has been unveiled in the UK, with the aim of building on the UK’s pandemic legacy and helping develop life-saving new vaccines that will fight ‘Disease X‘, a term used because what might trigger the next pandemic is unknown. Read More

#News #Trending News

Vaccine
#Covid booster #Covid-19 #HIPRA Human Health #Immunology / Virology & Vaccines #MHRA

Bimervax Covid-19 vaccine authorised in UK

Bimervax from HIPRA Human Health has been authorised in the UK after meeting the Medicines & Healthcare products Regulatory Agency’s (MHRA) required safety, quality and effectiveness standards. It becomes the ninth Covid-19 vaccine to be authorised by the UK’s independent medicines regulator. Bimervax combines… Read More

#News

Genetic engineering RNA
#Antisense Oligonucleotides (ASOs) #circular RNAs #Immunology / Virology & Vaccines #mRNA #RNA sequencing #siRNA

World RNA Day: What impact has RNA had on drug discovery?  

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the… Read More

#Exclusive Content

Antibiotics
#AMR #Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Immunology / Virology & Vaccines #University of Queensland

Global crisis of antibiotic resistance is “inevitable”

A report by University of Queensland (UQ) researchers has warned a global crisis of antibiotic resistance is inevitable, despite promising developments in new antibiotics. The Centre for Superbug Solutions at UQ’s Institute for Molecular Bioscience has monitored the clinical pipeline for more than a decade, with… Read More

#Editor's Choice #News